Niraparib
- Generic Name
- Niraparib
- Brand Names
- Zejula
- Drug Type
- Small Molecule
- Chemical Formula
- C19H20N4O
- CAS Number
- 1038915-60-4
- Unique Ingredient Identifier
- HMC2H89N35
- Background
Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, fallopian tube, or primary peritoneal can...
- Indication
Niraparib is indicated for the maintenance treatment of adult patients with advanced or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.
...
- Associated Conditions
- Advanced Epithelial Ovarian Cancer, Advanced Primary Peritoneal Carcinoma, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Advanced Fallopian Tubes Cancer
- Associated Therapies
- Maintenance therapy
A MolEcularly Guided Anti-Cancer Drug Off-Label Trial
- Conditions
- Interventions
- First Posted Date
- 2019-12-04
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Uppsala University Hospital
- Target Recruit Count
- 167
- Registration Number
- NCT04185831
- Locations
- 🇸🇪
Skane University Hospital, Lund, Sweden
🇸🇪Uppsala University Hospital, Uppsala, Sweden
🇸🇪Sahlgrenska University Hospital, Gothenburg, Sweden
Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)
- Conditions
- Interventions
- First Posted Date
- 2019-11-20
- Last Posted Date
- 2024-11-26
- Target Recruit Count
- 204
- Registration Number
- NCT04170153
- Locations
- 🇯🇵
National Cancer Center Hospital - Dept of Experimental Therapeutics, Chuo-ku, Japan
🇨🇳Beijing Cancer Hospital, Beijing, China
🇪🇸Hospital Universitari Vall d'Hebron - Oncology Dept., Barcelona, Spain
A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer
- First Posted Date
- 2019-11-12
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 267
- Registration Number
- NCT04159155
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Trial of Maintenance With Niraparib- Uterine Serous Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2019-09-06
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Northwell Health
- Target Recruit Count
- 45
- Registration Number
- NCT04080284
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Cancer Institute at Lenox Hill, New York, New York, United States
🇺🇸Imbert Cancer Center Northwell Health, Bay Shore, New York, United States
Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- University of Oklahoma
- Target Recruit Count
- 66
- Registration Number
- NCT04068753
- Locations
- 🇺🇸
Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
🇺🇸Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States
🇺🇸University of Virginia Cancer Center, Charlottesville, Virginia, United States
Niraparib With Standard Combination Radiation Therapy and Androgen Deprivation Therapy in Treating Patients With High Risk Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-07-30
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 22
- Registration Number
- NCT04037254
- Locations
- 🇺🇸
Benefis Sletten Cancer Institute, Great Falls, Montana, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸University of Arizona Cancer Center-Orange Grove Campus, Tucson, Arizona, United States
Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects
- Conditions
- Interventions
- First Posted Date
- 2019-07-24
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Marc Dall'Era, MD
- Target Recruit Count
- 30
- Registration Number
- NCT04030559
- Locations
- 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer
- First Posted Date
- 2019-06-12
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- Emory University
- Target Recruit Count
- 40
- Registration Number
- NCT03983993
- Locations
- 🇺🇸
Emory Saint Joseph's Hospital, Atlanta, Georgia, United States
🇺🇸Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Emory University Hospital Midtown, Atlanta, Georgia, United States
Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)
- First Posted Date
- 2019-06-12
- Last Posted Date
- 2022-03-18
- Lead Sponsor
- Shanghai Gynecologic Oncology Group
- Target Recruit Count
- 167
- Registration Number
- NCT03983226
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, China
🇨🇳Zhejiang Cancer Hospital, Hangzhou, China
🇨🇳Fudan University Shanghai Zhongshan Hospital, Shanghai, Shanghai, China
A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-06-11
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Tesaro, Inc.
- Target Recruit Count
- 785
- Registration Number
- NCT03981796
- Locations
- 🇬🇧
GSK Investigational Site, Truro, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.